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Abstract 
 Atherosclerosis, the underlying cause of cardiovascular diseases such as 
myocardial infarction, cerebrovascular accident and peripheral vascular disease, is 
the leading cause of global mortality. Current therapies against atherosclerosis, which 
mostly target the dyslipidemia associated with the disease, have considerable residual 
risk for cardiovascular disease together with various side effects. In addition, the 
outcomes from clinical trials on many promising pharmaceutical agents against 
atherosclerosis (e.g. low-dose methotrexate, inhibitors against cholesteryl ester 
transfer protein) have been disappointing. Nutraceuticals such as probiotic bacteria 
have therefore generated substantial recent interest for the prevention of 
atherosclerosis and potentially as add-ons with current pharmaceutical drugs. This 
review will discuss our current understanding of the anti-atherogenic actions of 
probiotics from pre-clinical and clinical studies together with their potential underlying 
mechanisms of action. 
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1. Introduction  
 Cardiovascular disease (CVD) is responsible for one in three global deaths and 
poses a substantial economic burden.[1-2] Atherosclerosis is the primary cause 
underlying CVD-related morbidity and mortality.[1-2] It is a chronic inflammatory disease 
of the vasculature featuring slow onset with a marked increase in the elderly 
population.[1-2] The progression of atherosclerosis is largely determined by common 
modifiable risk factors (e.g. dyslipidemia, smoking, hypertension, diabetes, obesity) 
and various unmodifiable factors (e.g. age, male gender, ethnicity and genetic 
predisposition such as familial hypercholesterolemia (FH) and Tangier disease).[3-4] 
The most important causal agents of atherosclerosis are apolipoprotein (apo) B-
containing lipoproteins of which low-density lipoprotein (LDL) has long been regarded 
as the principle driver for the initiation and progression of atherosclerotic plaques.[1-4] 
Indeed, a more recent evaluation of evidence from a range of meta-analyses of 
genetic, epidemiological and clinical studies demonstrated an unequivocal causality 
between LDL-cholesterol (LDL-C) and atherosclerosis-associated CVD.[5] The 
majority of current therapies therefore aim to reduce plasma LDL-C; however, they are 
associated with considerable residual risk for CVD together with various side effects.[1-
2] This, together with many promising pharmaceutical leads failing at the clinical level, 
has fuelled substantial interest in harnessing the potential of nutraceuticals in the 
prevention of atherosclerosis and their use as add-ons with current pharmaceutical 
agents.[1-2,6] In this regard, many recent studies have highlighted the promise of 
probiotic bacteria. This review will discuss the pathogenesis of atherosclerosis, current 
therapies and their limitations, and probiotics as anti-atherogenic agents together with 
the mechanisms underlying their actions. 
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2. Pathogenesis of atherosclerosis  
Atherosclerosis is an inflammatory disease of the medium and large arteries 
occurring predominantly at sites of low shear stress and disturbed laminar flow.[4] 
Endothelial cells of the arteries are particularly sensitive and susceptible to shear 
stress induced by laminar blood flow, especially at sites of arterial branching and 
curvature where disturbed flow contributes in part to the subendothelial accumulation 
of apoB-containing lipoproteins and lesion initiation.[3-4,7] Many recent reviews have 
discussed the pathogenesis of atherosclerosis and the readers are therefore directed 
to these for more details.[1-4] Briefly, the accumulation of LDL in the subendothelial 
space, either via passive diffusion or scavenger receptor (SR)-B1-driven 
transcytosis,[8] triggers an inflammatory response and activation or dysfunction of the 
endothelium.[1-4] The endothelial cells in such a state express a range of adhesion 
molecules and chemokines which aids in the recruitment of circulating leukocytes, 
particularly monocytes, to the site of LDL accumulation.[1-2] Through a process of 
adherence and rolling, monocytes transmigrate into the intima, where they 
differentiate into macrophages.[4] A wide spectrum of macrophage phenotypes has 
been identified, such as pro-inflammatory M1 and anti-inflammatory M2, with 
polarization influenced by the intimal micro-environment.[3-4] M1 polarized, pro-
inflammatory macrophages represent the most abundant immune cells residing in 
atherosclerotic plaques, originating either from the transmigration and differentiation 
of circulating monocytes[1-4] or from local proliferation, which has recently been shown 
to significantly contribute to lesional macrophage accumulation.[9-10]  
The LDL trapped in the subendothelial space undergoes both enzymatic and 
non-enzymatic modifications by processes such as glycation, aggregation or 
oxidation.[3] Oxidation represents one of the most common modifications leading to the 
 6 
formation of oxidized LDL (oxLDL), a highly pro-inflammatory and pro-atherogenic 
molecule and a key instigator of atherogenesis.[3] During the oxidation of LDL, 
oxidation-specific neoepitopes are generated, which are not only immunogenic but 
prominent targets of pattern recognition receptors (PRRs).[11] Under atherosclerotic 
conditions, monocyte-derived macrophages exhibit many morphological changes, 
including decreased ability to migrate, a feature that contributes to the failure of 
inflammation resolution and to plaque progression, and increased expression of cell 
surface PRRs, such as SRs A and CD36, that are able to uptake modified LDL.[3,12] 
Macrophage SRs are classic PRRs, which readily recognize these oxidation-specific 
epitopes on oxLDL particles.[11] Macrophage uptake of native LDL via LDL receptors 
is negatively regulated by an increase in intracellular cholesterol levels.[3] In contrast, 
the uptake of modified LDL via macrophage SRs is unregulated, rapid and 
excessive.[3] In addition, other processes such as macropinocytosis, a form of fluid-
phase endocytosis, contributes significantly to the uptake of LDL and modified LDL.[13] 
The cholesterol efflux machinery normally functions to transport excess intracellular 
cholesterol out of the cell either by high-density lipoprotein (HDL)-mediated passive 
diffusion, or to extracellular lipid acceptors for hepatic removal via reverse cholesterol 
transport (RCT).[3] RCT is a multi-step process responsible for the transport of excess 
cholesterol from peripheral tissues to the liver where it may be excreted via the bile 
system (see Section 11).[3] However, cholesterol efflux and associated RCT are 
compromised during atherosclerosis resulting in the formation of lipid-laden foam cells 
– the hallmark of atherosclerosis.[3] 
Cholesterol-induced cytotoxicity results in increased apoptotic and necrotic cell 
death.[1-4] Under normal conditions, apoptosis occurs at a very high rate and apoptotic 
cells are rapidly cleared via efferocytosis (clearance of apoptotic cells by phagocytes, 
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including macrophages).[14] In early lesions, the numbers of apoptotic macrophages 
balance with effective efferocytosis leading to reduced plaque cellularity.[14] However, 
in advanced lesions, efferocytosis is ineffective resulting in an accumulation of 
apoptotic and necrotic cells and associated debris.[14] As the atherosclerotic plaque 
advances, an inflammatory response regulated by the actions of several 
cytokines[3,4,15,16], together with continuous accumulation of apoptotic cells and debris, 
pro-atherogenic lipoproteins and lipoprotein remnants, leads to secondary necrosis 
and the formation of a lipid-rich necrotic core.[1-4] Vascular smooth muscle cells 
(VSMCs) migrate from the media to the intima and contribute to extracellular matrix 
(ECM) remodelling and formation of a protective fibrous cap between the necrotic core 
and the lumen, which functions to stabilize the plaque.[1-4] VSMC also make significant 
contribution to foam cell formation.[17] In advanced disease with an enhanced 
inflammatory setting, protease action degrades the ECM, compromising the integrity 
of the protective cap.[1-4] Plaque vulnerability and eventual rupture results in the 
release of plaque contents into the lumen, thrombosis and subsequent clinical 
complications.[1-4] 
3. Current anti-atherogenic therapies, their limitations and the potential of 
nutraceuticals 
Statins often represent the first-line lipid-lowering therapy in global treatment 
guidelines.[2,18] Statins belong to a class of cholesterol-lowering pharmaceutical agents 
and are known for their ability to inhibit 3-hydroxy-3-methylglutaryl-CoA reductase, an 
enzyme involved in the rate limiting step of cholesterol biosynthesis.[2,18] Inhibition of 
this enzyme results in a reduction of circulating LDL-C, subsequently lowering 
cardiovascular risk.[2,18] In addition to this LDL-C-dependent activity, statins have been 
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reported to exert LDL-C-independent (pleiotropic) effects, including anti-inflammatory 
actions.[18] However, owing to the over-shadowing effect of cholesterol reduction on 
cardiovascular risk, the clinical significance of these pleiotropic effects remains 
controversial.[18] The maximum reduction in cardiovascular mortality that can be 
attributed to statin therapy is approximately 22% per 1 mmol/L reduction in LDL-C, 
and a substantial residual cardiovascular risk is therefore associated with statin 
therapy as reported by a large number of studies.[2,18] Furthermore, of those patients 
receiving statins, a small subset is unable to achieve target plasma cholesterol levels 
even at the highest possible dose, while further subsets suffer intolerable statin-
associated side effects such as myopathy.[19] Due to the limitations of statin therapy, 
a number of statin co-therapies with non-statin agents have been developed. One co-
therapy involves statins in combination with the lipid-lowering agent ezetimibe, 
designed to reduce cholesterol absorption in the intestine by modulating the action of 
Niemann-Pick C1-like 1 (NPC1L1) protein.[20] In IMPROVE-IT (Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial), the addition of ezetimibe to statin 
therapy in the long-term treatment of patients following acute coronary syndrome led 
to a significantly lower risk of cardiovascular events than that achieved with statin 
monotherapy.[20] No differences were seen in cardiovascular mortality or the rate of 
death from any cause though there were significant reductions in the rates of 
myocardial infarction and ischemic stroke.[20] Furthermore, a recent comparative meta-
analysis reported that statin-ezetimibe co-therapy was more effective in reducing the 
incidence of CVD in comparison to statin monotherapy.[21] Proprotein convertase 
subtilisin/kexin type 9 (PCSK9)-inhibitors have also shown potential as efficient lipid-
lowering agents.[22] PCSK9 is a serine protease which binds to the LDL receptor, 
inducing its intracellular degradation and thereby reducing the clearance of plasma 
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LDL-C.[22] Monoclonal antibodies targeting PCSK9, namely alirocumab and 
evolocumab, have shown success in lowering LDL-C and are currently approved for 
use in hypercholesterolemic patients who otherwise fail to respond to statin therapy.[22] 
Thus, in the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After 
an Acute Coronary Syndrome During Treatment With Alirocumab) clinical trial of 
18,924 participants, the risk of recurring cardiovascular events was reduced in patients 
with previous acute coronary syndrome who were on high intensity statin therapy when 
they received alirocumab compared to the placebo control.[23] In the FOURIER 
(Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With 
Elevated Risk) trial involving 27,564 participants with CVD and LDL-C of 70 mg/dL 
(1.8 mmol/L), evolocumab reduced both LDL-C and the risk of cardiovascular events 
compared to those receiving placebo.[24] However, due to the expensive nature of 
these treatments, they are restricted to high risk patients such as those with homo- or 
hetero-zygous FH.[22]  
In addition to lipid-lowering agents, a number of alternative therapies have been 
investigated, including HDL elevating agents and anti-inflammatory treatments.[25-32] 
Low levels of HDL are known to be associated with high cardiovascular risk as 
demonstrated in patients with Tangier disease, while increasing levels of HDL-C is 
known to lower the risk of CVD.[2,25] The beneficial effects of HDL and its negative 
correlation with CVD is thought to be due to its role in RCT of excess cholesterol from 
foam cells to the liver for biliary excretion.[2,3,25] In prospective epidemiologic studies, 
every 1 mg/dL increase in HDL was associated with a 2-3% decrease in 
cardiovascular risk, independent of LDL-C and triacylglycerol (TG) levels.[25] HDL-C 
represents a promising target for pharmacological intervention; however, studies 
report conflicting results.[25] For example, niacin has been shown to reduce CVD risk 
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by both lowering LDL-C and elevating HDL-C in pre-clinical studies.[25] However, in 
the Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular 
Events (HPS2-THRIVE) trial, niacin treatment did not significantly reduce major 
vascular events and was even associated with adverse effects.[26] Cholesteryl ester 
transfer protein (CETP) is responsible for the movement of esterified cholesterol from 
HDL to  VLDL and LDL, in exchange for TG.[27] Although lower CETP levels are known 
to promote HDL formation, clinical trials on several CETP inhibitors have failed.[27] 
Given the inflammatory nature of atherosclerosis disease, anti-inflammatory 
agents represent a promising therapeutic strategy for the reduction of cardiovascular 
risk; however, many promising candidates have failed in clinical trials.[28] In patients 
with high levels of the inflammatory marker, C-reactive protein (CRP), treatment with 
canakinumab, a monoclonal antibody that inhibits inflammation by blocking the 
cytokine interleukin (IL)-1 , resulted in significantly reduced incidence of 
atherosclerotic events than placebo in the CANTOS (Canakinumab Anti-inflammatory 
Thrombosis Outcomes Study) trial.[29] However, patients also became prone to 
infection and so treatment will have to be restricted to high risk patients.[29] Despite the 
promising success of IL-1  blockers to date, trials of alternative anti-inflammatory 
agents have reported fewer encouraging outcomes. For example, one potential anti-
inflammatory that is currently used in the treatment of rheumatoid arthritis is 
methotrexate.[4] However, the CIRT (Cardiovascular Inflammation Reduction Trial) 
trial of low-dose methotrexate failed to reduce the incidence of cardiovascular events 
in patients with hyperglycemia and high levels of CRP.[28,30] Additionally, the highly 
anticipated lipoprotein-associated phospholipase A2 inhibitor darapladib failed to 
reduce cardiovascular risk in two separate clinical trials; STABILITY (Stabilization of 
Atherosclerotic Plaque by Initiation of Darapladib Therapy) and SOLID-TIMI 52 (The 
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Stabilisation Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 
52).[31] The potential of anti-inflammatory agents to reduce the incidence of CVD 
remains the subject of investigation as the search continues for effective anti-
inflammatory therapies.[4] For example, bromodomain and extra-terminal (BET) 
proteins are epigenetic regulators of inflammation, lipoprotein metabolism and 
thromogenesis and the BETonMACE trial is investigating whether a selective BET 
protein inhibitor, apabetalone, improves cardiovascular outcomes in patients with 
acute coronary syndrome and diabetes.[32] 
An alternative approach for atherosclerosis intervention involves the use of 
nutraceuticals, defined as foods or dietary supplements with health benefits beyond 
their basic nutritional value.[1-2] A number of nutraceuticals have demonstrated anti-
atherogenic effects in preclinical studies and in human trials (reviewed in detail in [1]). 
Unlike pharmaceuticals, nutraceuticals are derived from natural compounds and are 
therefore considered safe for use over an extended period of time.[1-2] Among the most 
studied in human trials are omega-3 polyunsaturated fatty acids (PUFAs), 
polyphenols, phytosterols and vitamins.[1-2,33] Recently, the clinical trial -The Reduction 
of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), which 
was designed to address the residual cardiovascular risk in statin-treated patients with 
elevated TG, demonstrated success in further reducing cardiovascular risk.[34] In this 
study, icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid omega-3 
PUFA, was found to significantly reduce the risk of major adverse cardiovascular 
events by 25%.[34] In addition to these nutraceuticals, recent studies have revealed an 
association between atherosclerosis-associated CVD and gut microbial dysbiosis,[35] 
and probiotic bacteria have been highlighted as potential candidates for 
atherosclerosis intervention.  
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4. Probiotics in atherosclerosis 
Composed of approximately 1 x 1014 bacteria, the gut microbiota is an essential 
mediator in health and disease and can be influenced by many factors, including host 
genetics, diet, stress and disease state.[36] The intestinal barrier is an epithelial 
monolayer which forms a primary interface preventing the diffusion of potentially 
injurious factors from the intestinal lumen into the tissue and systemic circulation.[36] 
Dysbiosis in the gut compromises the intestinal barrier function leading to the leakage 
of lipopolysaccharide (LPS) and other bacterial components (e.g. peptidoglycans) into 
the circulation, triggering an inflammatory response that drives atherosclerosis.[35-36] 
LPS is able to promote monocyte recruitment to the activated endothelium and 
subsequent macrophage foam cell formation by stimulating the uptake of modified 
LDL and reducing the efflux of cholesterol from foam cells.[35,37] LPS is also able to 
induce vascular inflammation either directly or via the production of pro-inflammatory 
factors from immune cells.[37] Toll-like receptors (TLRs) are a family of recognition 
receptors for pathogen associated molecular patterns (PAMPs), activated in response 
to bacterial components such as LPS.[35-37] Upon activation of TLRs, an inflammatory 
response is orchestrated via intracellular signaling cascades that induces the 
expression of many pro-inflammatory cytokines and chemokines.[35-37]  Furthermore, 
microbiota-derived metabolites, including atherogenic molecules such as choline and 
trimethylamine N-oxide (TMAO) link the gut microbiome to disease (see Section 
10).[37]  
Probiotics are defined as microorganisms that when ingested in adequate 
amounts, confer a health benefit to the host.[35] Probiotics are ‘good’ bacteria that may 
be exploited for their ability to combat dysbiosis and promote gut health.[35] Probiotic 
bacteria have beneficial effects on the host by producing vitamins K and B2, together 
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with short chain fatty acids (SCFAs) such as acetate, butyrate or propionate, which 
are used as fuel by the intestinal flora and colonocytes.[38] Indeed, bacterial butyrate 
has been shown to prevent atherosclerosis in mouse model systems.[39] Importantly, 
probiotics are known to improve gut barrier function via strengthening of the epithelial 
tight junctions.[40] By reducing gut leakage, probiotic bacteria strengthen 
immunological and non-immunological gut barrier function, and reduce the 
translocation of microbial immunogens.[41] The implication of host gut microbiota in 
disease and the ability of probiotics to promote overall gut health has led to an 
explosion of research showing therapeutic benefits in a vast range of disease states. 
Indeed, probiotics are currently used for the prevention and treatment of inflammatory 
bowel diseases, irritable bowel syndrome, gluten intolerance, gastroenteritis and 
antibiotic-associated diarrhoea.[40] More recent data implicates the gut microbiota in a 
diverse range of diseases via the gut-brain axis, gut-lung axis, gut-liver axis and gut-
vascular axis.[35,37,40,41] 
Probiotic supplementation has been shown to beneficially modify a number of 
major atherosclerosis-associated cardiovascular risk factors, including 
hypercholesterolemia, dyslipidemia, hypertension and chronic inflammation (Figure 
1). The anti-atherogenic effects of several different probiotic strains, as reported in 
human and animal studies, are summarized in Table 1. It should, however, be noted 
that not all probiotics are anti-atherogenic. For example, Lactobacillus reuteri had no 
effect on atherosclerosis in apolipoprotein E deficient mice (ApoE-/-; a widely used 
model of atherosclerosis) fed a high fat diet (HFD).[64] 
 
5. Probiotics and lesion formation 
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Only a few studies have investigated the effect of probiotic supplementation on 
atherosclerotic plaque formation (Table 1). VSL#3 is a consortium of 8 lyophilized 
lactic acid bacterial strains (Bifidobacterium longum, Bifidobacterium infantis, 
Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus 
delbrueckii subsp. bulgaricus, Lactobacillus plantarum, and Streptococcus salivarius 
subsp. thermophilus).[42] Chan and colleagues have demonstrated significantly 
reduced HFD-induced lesion development in ApoE-/- mice when supplemented with 
the VSL#3 consortium, in addition to reduced vascular inflammation and significant 
reductions in plasma levels of s-intercellular adhesion molecule-1, s-vascular cell 
adhesion molecule-1 and s-E-selectin.[42] Another study investigated the effect of two 
Lactobacillus strains (L. acidophilus ATCC 4356 and 4962) on atherosclerosis 
development in ApoE-/- mice.[48] The authors reported a dramatic reduction in 
atherosclerotic lesion area in the L.4356 group; however, no significant effect was 
observed in the L.4962 group.[48] In the same study, the plasma levels of total 
cholesterol (TC) and non-HDL-C-containing lipoproteins were significantly reduced 
and a significant decrease in cholesterol absorption was observed.[48] In a separate 
study, L. acidophilus ATCC 4356 was again shown to reduce atherosclerosis lesion 
development in ApoE-/- mice, in addition to reduced plasma oxLDL and tumour 
necrosis factor (TNF)-α levels, and increased plasma IL-10 indicating a beneficial 
effect on inflammatory markers.[47] 
6. Probiotics and dyslipidemia 
The beneficial effects of probiotic supplementation on plasma lipids is well 
documented and a large number of meta-analyses concur that probiotics are 
associated with a significant reduction in TC and LDL-C.[65-67] One meta-analysis of 
the effects of probiotic supplementation on lipid profiles of normal and 
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hypercholesterolemic individuals included 26 clinical studies utilizing fermented milk 
products and probiotic supplements.[65] Probiotic supplementation resulted in a 
significant reduction in plasma TC and LDL-C, with no change in HDL-C or TG. 
Subgroup analysis revealed a statistically greater reduction in TC and LDL-C with 
long-term (>4 weeks) probiotic intervention. The authors highlighted Lactobacillus 
acidophilus as the strain most effective in reducing TC and LDL-C.[65] A further meta-
analysis included 15 clinical studies with 788 participants.[66] Significant pooled effects 
of probiotics were achieved for the reduction of TC, LDL-C, body mass index and 
inflammatory markers.[66] Subgroup analysis revealed statistically greater reductions 
in TC and LDL-C with long-term (>8 weeks) intervention, and with multiple versus 
single probiotic strains. Again Lactobacillus acidophilus was highlighted as the most 
effective strain in reducing LDL-C.[66] A more recent meta-analysis of 32 clinical trials 
and 1971 patients also reported a significant reduction in TC with probiotic 
supplementation.[67] Subgroup analysis suggested that a difference in baseline TC as 
well as the duration of intervention may significantly impact results; however, the 
probiotic strain and the dose were found to have no significant influence.[67] Although 
there is evidence that probiotic bacteria are able to influence host lipid profiles, the 
exact mechanisms of action remain poorly understood (see Section 11).[65-67]  
7. Probiotics and endothelial dysfunction 
Endothelial dysfunction mediated by various CVD risk factors is a critical 
early event in the pathogenesis of atherosclerosis.[1-4] Probiotics have been shown to 
attenuate several pro-atherogenic changes associated with endothelial dysfunction via 
multiple mechanisms, including increasing availability of nitric oxide (NO), improving 
oxidative stress, restoring endothelial architecture, recruitment of endothelial 
progenitor cells and improving vascular inflammation.[68] For example, ingestion of 
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VSL#3 attenuated endothelial dysfunction that was associated with improved vascular 
oxidative stress in the mesenteric artery of rats following common bile duct ligation.[69] 
In addition, Lactobacillus coryniformis CECT5711 reversed endothelial dysfunction in 
obese mice by increasing NO bioavailability.[70] The probiotic kefir also improved 
endothelial dysfunction in spontaneously hypertensive rats by decreasing ROS 
production, increasing NO bioavailability and restoring the recruitment of endothelial 
progenitor cells.[71] Similarly, Lactobacillus fermentum improved tacrolimus-induced 
endothelial dysfunction by reducing vascular oxidative stress and inflammation.[72] The 
beneficial actions of probiotics on endothelial dysfunction has also been seen in some 
human studies.[68,73] Thus, a clinical trial of 81 women showed that multispecies 
probiotic supplementation improved several parameters of endothelial dysfunction 
[e.g. systolic blood pressure (BP), vascular endothelial growth factor, pulse wave 
velocity, inflammatory cytokines).[73] However, no significant changes in endothelial 
dysfunction were observed in a study of 30 subjects with metabolic syndrome that 
received Lactobacillus casei Shirota.[74] It is therefore essential that further research is 
carried out on the impact of probiotics on endothelial dysfunction especially because 
of its importance not only in atherosclerosis but other diseases such as diabetes, 
obesity and chronic renal failure. 
8. Probiotics and inflammation  
Probiotics are known to modify the host immune responses.[75-76] However, 
interactions between probiotic bacteria, the gut and the host immune systems are 
highly complex and despite increasingly growing clinical evidence, remains poorly 
understood.[75-76] In a recent study, a reduction in atherosclerotic lesion development 
was accompanied by the suppression of interferon- -producing CD4+ T cells and pro-
inflammatory cytokine production in Pediococcus acidilactici R037-treated mice.[45] In 
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addition to a reduction in pro-inflammatory T cells, probiotic bacteria have been shown 
to decrease inflammation via an increase in regulatory T cells.[77] DNA from the VSL#3 
consortium has been shown to limit epithelial proinflammatory responses in vivo and 
in vitro, and to attenuate systemic release of TNF-α in response to Escherichia coli 
DNA injection.[78] In addition, VSL#3 was found to reduce vascular inflammation, 
including the expression of adhesion proteins, in ApoE-/- mice fed a HFD.[42] In a 
separate study, VSL#3 DNA was shown to exert anti-inflammatory effects via TLR9 
signaling;[79] interestingly, the authors concluded that the protective anti-inflammatory 
effects of the probiotics were mediated via their own DNA rather than metabolites, and 
that TLR9 signaling is essential in mediating this effect.  
9. Probiotics, hypertension and hyperglycemia  
In a meta-analysis of the effect of probiotics on hypertension, the authors 
reported a significant reduction in systolic and diastolic BP.[80] Subgroup analysis 
revealed a greater reduction achieved with long-term treatment duration (>8 weeks), 
where durations of <8 weeks showed no significant changes.[80] Additionally, the 
inclusion of multiple compared to single strains, and daily consumption of doses ≥1011 
colony forming units, were associated with significant reductions in both systolic and 
diastolic BP.[80] Furthermore, a recent meta-analysis of 11 clinical studies also 
reported beneficial effects of probiotic supplementation on both hypertension and 
dyslipidemia in diabetic patients.[81] Pooled data demonstrated significantly reduced 
systolic and diastolic BP in addition to plasma LDL-C, TC and TG.[81] Similarly, some 
studies investigating probiotic supplementation in relation to type 2 diabetes and 
insulin resistance have shown success.[82-84] In a meta-analysis of 22 cohort studies 
and 579,832 individuals, total dairy consumption was inversely associated with type 2 
diabetes risk, where yogurt consumption was reported to be particularly effective.[82] A 
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separate meta-analysis of 10 clinical trials reported significantly reduced fasting blood 
glucose, systolic and diastolic BP, and  plasma TC, LDL-C and TG in type 2 diabetic 
patients with probiotic supplementation.[85] Further studies have demonstrated 
probiotic-associated reduction in blood glucose levels and/or insulin resistance with 
various strains of Lactobacillus, Bifidobacterium and Streptococcus.[51,52,62] However, 
the association between probiotic treatment and diabetes is less clear with a small 
number of studies showing no such association.[86] For example, in a recent clinical 
trial, type 2 diabetic patients receiving a consortium of 8 different probiotic strains 
exhibited significantly higher median glucose levels, in addition to higher circulating 
TC and LDL-C.[86]  
10. Probiotics and TMAO  
In addition to their effects on atherogenic risk factors, probiotic bacteria have 
been shown to affect the production of potentially atherogenic metabolites.[35,37] A key 
metabolite currently receiving attention for its strong association with atherosclerosis 
is TMAO.[87] The bacterial metabolite trimethylamine is produced by the gut microbiota 
from dietary choline, phosphatidylcholine and L-carnitine, then oxidized to TMAO in 
the liver and released into the circulation.[87] It has been suggested that TMAO 
contributes to atherosclerosis in part by promoting macrophage foam cell formation in 
atherosclerotic lesions as well as ineffective RCT and disruption of lipid 
homeostasis.[76,87-88] For example, TMAO increased the macrophage expression of 
SR CD36, thereby promoting the uptake of modified LDL, and reduced the expression 
of enzymes involved in the synthesis of bile acids that are involved in RCT.[35] In 
addition, TMAO has been shown to promote vascular inflammation, activation of 
arterial endothelial cells and thrombosis.[37] Probiotic treatment has been shown to 
reduce levels of TMAO in correlation with decreased atherosclerosis development;[89] 
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however, this effect is strain specific. A recent study investigated potential TMAO-
lowering property of five different probiotic strains.[49] Only Lactobacillus plantarum 
ZDY04 was able to significantly reduce plasma TMAO, and it was suggested that this 
effect was achieved via remodelling of the gut microbiota.[49] Furthermore, 
Lactobacillus plantarum ZDY04 significantly attenuated the development of TMAO-
induced atherosclerosis in ApoE-/- choline-fed mice[49] In a similar study, plasma TMAO 
was significantly reduced in choline-fed mice treated with Enterobacter aerogenes 
ZDY01, and a similar remodelling of gut microbiota was demonstrated.[90] However, 
the beneficial effect of probiotic bacteria on TMAO production is strain specific and a 
human study investigating Streptococcus thermophilus (KB19), Lactobacillus 
acidophilus (KB27), and Bifidobacteria longum (KB31), reported no change in TMAO 
levels.[91] Similarly, supplementation with Lactobacillus casei Shirota for 12 weeks had 
no effect on TMAO levels in patients with metabolic syndrome.[82]  
11. Potential mechanisms underlying the anti-atherogenic actions of 
probiotics 
The molecular mechanisms underlying the anti-atherogenic actions of 
probiotics are not fully understood. However, what is clear is that probiotics act at 
multiple steps (Figure 2). For example, probiotics combat gut dysbiosis by 
strengthening the epithelial tight junctions, which then prevents the leakage of 
microbial immunogens (e.g. LPS) and other pro-atherogenic factors such as TMAO.[35] 
This is achieved in part via production of glucagon-like peptide 2 that modulates the 
expression of intestinal tight junction proteins.[35] The role of TMAO in atherosclerosis 
has been described above (Section 10). Leakage of LPS into systemic circulation is a 
major pro-atherogenic contributor during dysbiosis.[35] LPS is known to promote 
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inflammation by binding to cell surface TLR4 receptor that are expressed at high levels 
in myelomonocytic cells.[35] Signaling by LPS involves a cell surface complex of TLR4 
and its co-receptors cluster of differentiation 14 and myeloid differentiation protein-1. 
The intracellular domain of TLR4 then activates many signaling pathways leading to 
increased synthesis of pro-inflammatory molecules such as cytokines and 
chemokines, hence promoting inflammation in plaques.[35] Thus, the chemokines 
stimulate the recruitment of monocytes to the activated arterial endothelial cells, 
thereby increase plaque macrophage burden and associated inflammation.[35] LPS 
and pro-inflammatory cytokines produced by its actions also promote macrophage 
foam cell formation in atherosclerotic plaques.[35] LPS inhibits the actions of liver X 
receptors (LXR), which stimulate macrophage cholesterol efflux.[35] In addition, pro-
inflammatory cytokines produced by the action of LPS inhibit the expression of key 
transporters (ATP-binding cassette transporters A1 and G1) that also stimulate 
cholesterol efflux from foam cells.[35] The increased production of pro-inflammatory 
cytokines also affects risk factors such as hypertension by promoting oxidative stress 
and the levels of oxLDL.[35] Thus, high levels of oxLDL inhibit the action of nitric oxide 
synthase, thereby reducing the levels of the vasodilator NO, and increase the 
production of the vasoconstrictor endothelin-1.[35]  
Primary bile acids are synthesized from cholesterol in the liver and secreted 
into the small intestine via the gall bladder where they aid in the digestion of lipids via 
emulsification.[93] About 95% of the bile acids are reabsorbed back from the small 
intestine though some pass through the feces, thereby providing a route for the body 
to eliminate cholesterol.[35,37] The enterohepatic circulation of bile acids is tightly 
regulated via the hepatic farnesoid X receptor (FXR) as high levels of bile acids are 
toxic to the cells.[93] FXR modulates the transcription of many enzymes involved in the 
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synthesis, conjugation, detoxification and transport of bile acids.[93] Thus, activation of 
hepatic FXR by bile acids inhibits the expression of cholesterol 7-hydroxylase 
(CYP7A1), a rate limiting enzyme in the de novo biosynthesis of bile acids from 
cholesterol.[93] FXR does not directly bind to the CYP7A1 promoter but acts via 
induced expression of small heterodimer partner (SHP), which then inhibits the 
transcription of the CYP7A1 gene by suppressing the activity of liver receptor 
homologue 1, a transcription factor involved in transactivation of CYP7A1[93] FXR also 
suppresses CYP7A1 expression via mouse fibroblast growth factor-15-c-Jun N-
terminal kinase (FGF15-JNK) axis (FGF19-JNK axis in humans).[93] FGF15/19 is 
secreted by the intestine and returns to the liver via enterohepatic circulation and acts 
via FGF receptor 4.[93] These pathways are affected by certain probiotics with bile salt 
hydrolase (BSH) activity, which makes a major contribution to their cholesterol 
lowering activities.[35,37,94,95] BSHs deconjugate primary bile acids forming 
deconjugated secondary bile salts, which are less soluble and are less efficiently 
reabsorbed from the intestine.[94-97] Deconjugated bile salts are therefore excreted in 
the feces, which creates greater demand for the de novo synthesis of bile acids to 
replace those lost in the feces.[33,35, 96-97] As cholesterol is a precursor of bile salts, this 
deconjugation and loss of bile acids results in a cholesterol-lowering effect in part via 
increased mobilization of plasma cholesterol by the liver for de novo bile acid synthesis 
via inhibition of FXR and thereby increased transcription of the CYP7A1 gene.[35,37, 96-
97] Deconjugated bile acids are also less efficient in the solubilization and absorption 
of lipids in the gut leading to reduced absorption of cholesterol from the intestinal 
lumen.[35,37,96-97]  
Some probiotics are also able to inhibit the expression of FXR and/or SHP, and 
thereby increase the expression of CYP7A1, independent of their BSH activity.[35,37,96-
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97] This together with increased expression of the LDL receptor induces the liver uptake 
of cholesterol and its subsequent metabolism into primary bile acids. However, other 
mechanisms have also been identified.[98-101] For example, Lactobacillus acidiphilus 
K301 inhibited atherogenesis in HFD-fed ApoE-/- mice via a mechanism involving 
increased macrophage cholesterol efflux and associated RCT via production of 24(S), 
25-epoxycholesterol, an endogenous ligand for LXRs, which induces an anti-foam cell 
and anti-inflammatory transcriptional program.[98] Lactobacillus acidophilus ATCC 
4356 also prevented atherosclerosis in HFD-fed ApoE-/- mice by stimulation of 
macrophage cholesterol efflux and RCT via activation of the LXR pathway.[48] In 
addition, intestinal cholesterol absorption was inhibited by modulation of NPC1L1 
expression.[48] This correlates well with in vitro studies in Caco-2 enterocytes that 
demonstrated reduced absorption of cholesterol by Lactobacillus rhamnosus 
BFE5264, Lactobacillus plantarum NR74 and Lactobacillus acidophilus via 
suppression of NPC1L1 expression.[99-100] Promotion of cholesterol efflux in 
enterocytes via induced expression of ABCG5/8 also represents another mechanism 
for probiotic-mediated decrease in hypercholesterolemia as demonstrated by studies 
on Caco-2 cells with Lactobacillus rhamnosus BFE 5264 and Lactobacillus plantarum 
NR74.[101] As detailed above, some probiotics can also induce the expression of LXR 
that is involved in transcriptional activation of the ABCG5/8 genes.[48,98] Probiotics 
have also been shown to bind to or even use cholesterol from the intestine by 
incorporation into cellular membranes.[96] In addition, probiotics are able to metabolize 
cholesterol to coprostanol, which can ultimately be lost in the feces and thereby reduce 
intestinal cholesterol absorption.[96] 
Mechanisms of immunomodulation have also been investigated and thought to 
be achieved via changes in cytokine production and modulation of associated 
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signaling pathways in intestinal epithelial and immune cells.[38,102-103] This has been 
demonstrated via probiotic release of bioactive metabolites and immunomodulatory 
factors.[38,102-103] SCFAs, such as butyrate, propionate and acetate, produced by the 
probiotic bacteria have multiple anti-atherogenic actions.[38] Butyrate in particular has 
been shown to decrease adhesion of monocytes to the activated endothelium and the 
expression of pro-inflammatory cytokines and adhesion proteins by inhibiting the 
cytoplasmic to nuclear translocation of nuclear factor-B (NF-B).[38-39] Many of the 
actions of SCFA are mediated via binding to cell surface G-protein coupled receptors 
and associated signaling pathways in target cells.[38] In addition, histamine derived 
from Lactobacillus reuteri suppressed pro-inflammatory TNF production via 
transcriptional regulation through protein kinase A and extracellular signal-regulated 
kinase signaling.[104]  Furthermore, S-layer protein A produced by the probiotic 
Lactobacillus acidophilus NCFM has been shown to bind to the intestinal dendritic cell 
surface receptor (dendritic cell-specific ICAM-3-grabbing nonintegrin) to induce the 
production of anti-inflammatory IL-10 in a dose-dependent manner.[105] Probiotics can 
also exert anti-inflammatory actions by modulating the expression of key transcription 
factors or microRNAs (miRNAs) implicated in pro-inflammatory signalling.[47,106] For 
example, Lactobacillus acidophilus ATCC 4356 attenuated the HFD-induced levels of 
TNF- and markers of oxidative stress, and reversed the reduction in IL-10 levels, in 
ApoE-/- mice via a mechanism involving inhibition of NF-B translocation from the 
cytoplasm to the nucleus.[47] In relation to miRNAs, Lactobacillus acidophilus was 
found to protect apoptosis and necrosis of human endothelial cells induced by LPS 
stimulation and this was associated with decreased expression of pro-inflammatory 
miR-155 and increased expression of anti-apoptotic mIR-21.[106] In addition, in dextran 
sodium suphate model of mouse colitis, the probiotics Lactobacillus fermentum, 
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Lactobacillus salivarius or Saccharomyces boulardii reduced the expression of pro-
inflammatory miR-155 and miR-223 and this was associated with intestinal anti-
inflammatory effects.[107,108] However, further research is required on the impact of 
probiotics on the expression of miRNAs associated with atherosclerosis and the 
impact of such changes on key cellular processes associated with the disease. 
 
Conclusions 
 A large body of evidence suggests a beneficial role for probiotic bacteria in the 
management of many atherogenic risk factors. Lactobacillus acidophilus in particular 
has shown promise in many human and animal studies where a variety of strains have 
had significant beneficial effects on atherosclerotic plaque development, plasma lipid 
profile, pro-inflammatory markers, and even insulin resistance and blood glucose 
levels (Table 1). This makes probiotics a promising nutraceutical in the prevention and 
treatment of atherosclerosis. However, many anti-atherogenic effects are subject to 
strain specific variation and a number of further studies have shown no effect, or even 
pro-atherogenic effects of probiotic treatment.[35-37,64,96,97] Differences in experimental 
design, such as concentration and duration of treatment, together with model systems 
used may have contributed to the discrepancy in the literature. Moreover, little is 
understood about the mechanisms underlying the observed effects of probiotics on 
host health. Future studies should focus on more mechanism-based animal studies 
using several different concentrations of various probiotics using a consistent 
experimental design. In addition, large clinical trials as REDUCE-IT[34] detailed in 
Section 3 are required. We are indeed entering an exciting phase in probiotic research.  
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Figure Legends 
 
Figure 1. Probiotics beneficially modulate a number of atherosclerosis-
associated cardiovascular risk factors.  
Abbreviations: HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TG, 
triacylglycerol; TMAO, trimethylamine N-oxide. 
 
Figure 2. The actions of probiotics are mediated via multiple mechanisms. 
 Many mechanisms are utilized by probiotic bacteria to mediate beneficial anti-
atherogenic actions, including combating gut dysbiosis and leakage of microbial 
immunogens, modulation of hepatic bile acid and cholesterol biosynthesis through 
pathways initiated by their bile salt hydrolase activity and/or direct actions on the 
expression and activities of key enzymes, or by production of beneficial metabolites 
(see text for more details). , increase; , decrease. Abbreviations: ABCA1/G1, ATP-
binding cassette transporter A1/G1; ABCG5/8, ATP-binding cassette transporter G5/8; 
BSH, bile salt hydrolase; FXR, farnesoid X receptor; IL-10, interleukin-10; LDLR, low-
density lipoprotein receptor; LPS, lipopolysaccharide; LXR, liver X receptor; mIR, 
micro RNA; NF-B, nuclear factor-B; NO, nitric oxide; NPC1L1, Niemann-Pick C1-
like 1; oxLDL, oxidized LDL; RCT, reverse cholesterol transport; SCFA, short chain 
fatty acids; SHP, small heterodimer partner; TMAO, trimethylamine N-oxide; TLR4, 
toll-like receptor 4. 
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Table 1. The athero-protective effects of probiotic bacteria 
Probiotics Anti-atherogenic 
effects 
Study group References 
VSL#3 Reduced lesion 
development; decreased 
vascular inflammation 
ApoE-/- mice 42 
L. rhamnosus 
GG 
Reduced lesion 
development; decreased 
plasma cholesterol, sE-
selectin, sICAM-1, 
sVCAM-1 and endotoxin 
ApoE-/- mice 43 
E. faecium 
CRL183 
Increased HDL-C; 
reduced TG; no change 
in plaque size 
Hypercholesterolemic 
rabbits 
44 
P. acidilactici 
R037 
Reduced lesion 
development; decreased 
production of pro-
inflammatory cytokines 
and CD4+ T cells 
ApoE-/- mice 45 
L. acidophilus 
145 and B. 
longum 913 
Increased HDL-C; 
reduced LDL:HDL ratio 
Human 46 
L. acidophilus 
ATCC 4356 
Reduced lesion 
development; decreased 
plasma cholesterol, 
oxLDL and TNF-a; 
increased plasma IL-10 
ApoE-/- mice 47-48 
L. plantarum 
ZDY04 
Reduced TMAO-induced 
lesion development; 
decreased plasma 
TMAO 
ApoE-/- mice 49 
L. acidophilus 
and B. bifidum 
Reduced TC, HDL-C 
and LDL-C 
Human 50 
VSL#3 Reduced TC, LDL-C, 
TG, hsCRP; increased 
HDL-C and improved 
insulin sensitivity 
Human 51 
S. thermophiles, 
L. bulgaricus, L. 
acidophilus LA5, 
B. lactis BB12 
Reduced TC, LDL-C, 
insulin resistance, 
postprandial blood 
glucose and fasting 
insulin 
Human 52 
L. plantarum 
LRCC 5273 
Reduced TC and LDL-C; 
induced expression of 
LXR-a  
C57BL/6 mice 53 
S. cerevisiae 
ARDMC1 
Reduced TC, LDL-C, TG Wister rats 54 
L. plantarum 
ECGC 13110402 
Reduced TC, LDL-C, 
TG; increased HDL-C 
Human 55 
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Figure 2 
  
Combats gut 
dysbiosis and 
leakage of microbial 
immunogens
↓LPS
• ↓TLR4 signaling and pro-inflammatory cytokine 
production
• ↓Inhibition of m*acrophage cholesterol efflux and RCT 
via LXRs or direct actions on ABCA1/G1
• ↓oxLDL-mediated foam cell formation, increased 
endothelial 1-mediated vasoconstriction and reduced 
NO-mediated vasodilation
↓TMAO
• ↓Foam cell formation via increased oxLDL uptake and 
reduced cholesterol efflux from foam cells
• ↓Inhibition of RCT via decreased expression of 
enzymes involved in the synthesis of bile acids
• ↓Vascular inflammation
BSH activity or 
direct actions of 
probiotics
• ↑BSH activity leading to increased hepatic bile acid 
synthesis (via inhibition of FXR) and increased de novo 
cholesterol synthesis 
• ↑Bile acid synthesis via direct inhibitory actions on FXR 
and SHP
• ↑Plasma clearance of LDL by increased hepatic 
expression of LDLR
• ↑Macrophage cholesterol efflux and RCT by 
endogenous production of LXR ligands
• ↓Intestinal absorption of cholesterol via NPC1L1
• ↑Cholesterol efflux in enterocytes via ABCG5/8
• ↑Binding to, and intestinal incorporation, of cholesterol 
into membranes
• ↑Metabolism of cholesterol to coprostanol
↓FXR, ↓SHP, 
↑LXR, ↑LDLR, 
↓NPC1L1, 
↑ABCG5/8
Production of 
metabolites
↑SCFA, 
↑histamine
• ↓Pro-inflammatory cytokine production via activation of 
NF-kB
• ↓ Adhesion and recruitment of monocytes to activated 
endothelium
• ↑Production of anti-inflammatory cytokines (e.g. IL-10)
• ↓Expression of pro-inflammatory miR-155 and miR-223
• ↑Expression of anti-apoptotic miR-21
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